A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.
JGH open : an open access journal of gastroenterology and hepatology（2022）
摘要
Ropeginterferon alfa-2b is efficacious and has a favorable safety profile as compared with the conventional pegylated interferon alfa-2b. This study together with previous Phase 2 data validated ropeginterferon alfa-2b to be a new treatment option for chronic hepatitis C genotype 2.
更多查看译文
关键词
chronic hepatitis B,chronic hepatitis C,chronic hepatitis C genotype 2,chronic viral hepatitis,clinical trial,ropeginterferon alfa‐2b
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要